Verrica Pharmaceuticals Management
Management criteria checks 2/4
Verrica Pharmaceuticals' CEO is Ted White, appointed in Dec 2017, has a tenure of 6.75 years. total yearly compensation is $3.50M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $187.28K. The average tenure of the management team and the board of directors is 4.5 years and 6.3 years respectively.
Key information
Ted White
Chief executive officer
US$3.5m
Total compensation
| CEO salary percentage | 17.1% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.5yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 17
With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For
Aug 16Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jul 21Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Vectoring Back In On Verrica Pharmaceuticals
Aug 31Verrica Pharmaceuticals reports insider buying
Jul 06Verrica Pharmaceuticals stock slides on proposed share offering
Jun 29Verrica Pharmaceuticals Should Receive Second CRL Today
May 24Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)
Mar 07Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 06Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook
Dec 17FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA
May 28Verrica Pharmaceuticals EPS beats by $0.32
May 07Verrica Pharma refiles US application for lead candidate in infectious skin disease
Dec 23Verrica Pharma receives final FDA minutes regarding NDA resubmission for VP-102 in molluscum
Nov 17Verrica Pharma' VP-102 successful in mid-stage study for genital warts
Nov 10Verrica Pharmaceuticals EPS misses by $0.02
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$81m |
| Dec 31 2023 | US$4m | US$601k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$2m | US$572k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$28m |
| Jun 30 2022 | n/a | n/a | -US$41m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | US$2m | US$550k | -US$35m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$34m |
| Dec 31 2020 | US$2m | US$485k | -US$43m |
| Sep 30 2020 | n/a | n/a | -US$37m |
| Jun 30 2020 | n/a | n/a | -US$33m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | US$1m | US$433k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$28m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$5m | US$400k | -US$21m |
| Sep 30 2018 | n/a | n/a | -US$20m |
| Jun 30 2018 | n/a | n/a | -US$15m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$24k | US$24k | -US$10m |
Compensation vs Market: Ted's total compensation ($USD3.50M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Ted's compensation has increased whilst the company is unprofitable.
CEO
Ted White (59 yo)
6.8yrs
Tenure
US$3,504,647
Compensation
Mr. Ted White has been the President and Chief Executive Officer at Verrica Pharmaceuticals Inc. since December 2017 and has been its Director since May 2018. Mr. White served as the President and General...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$3.50m | 0.24% $ 187.3k | |
| Chief Legal Officer | 6yrs | US$2.56m | 0.15% $ 119.1k | |
| Chief Financial Officer | 3.2yrs | no data | 0.011% $ 8.5k | |
| Chief Medical Officer | 4.2yrs | US$989.18k | 0.13% $ 98.2k | |
| Executive Vice President of Technical Operations | 4.9yrs | no data | no data | |
| Head of Drug Development | 4.1yrs | no data | no data |
4.5yrs
Average Tenure
59yo
Average Age
Experienced Management: VRCA's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$3.50m | 0.24% $ 187.3k | |
| Independent Director | 6.3yrs | US$119.19k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.2yrs | US$119.19k | 0% $ 0 | |
| Director | 8.8yrs | no data | 1.08% $ 836.4k | |
| Chairman of the Board | 8.8yrs | no data | 35.93% $ 27.8m | |
| Independent Director | 5.3yrs | US$119.19k | 0.023% $ 18.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.3yrs
Average Tenure
61yo
Average Age
Experienced Board: VRCA's board of directors are considered experienced (6.3 years average tenure).